drugset / Trial / NCT01638598

Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers

NCT01638598

Phase 1 Completed 80 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Safety,tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1021958 after single rising doses (SRD) in healthy Asian male volunteers

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1021958 Unknown

Indications

No indication recorded.